Honokiol is the alive
assumption of magnolia abstract that inhibits Akt-phosphorylation and promotes
ERK1/2 phosphorylation.
Honokiol shows pro-apoptotic
furnishings in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate,
articulate squamous corpuscle blight and colon blight corpuscle lines. Honokiol
is able on inducing apoptosis in SVR angiosarcoma cells. Analysis of SVR beef
with honokiol causes decreased phosphorylation of MAP kinase, akt, and c-src.
In addition, honokiol potentiates TRAIL-mediated apoptosis, and honokiol cytotoxicity
is partially abrogated by acrid antibodies to TRAIL. Honokiol aswell has
absolute antiangiogenic activity, in that honokiol blocks the phosphorylation
and rac activation due to VEGF-VEGFR2 interactions. Honokiol causes apoptosis
in CLL beef through activation of caspase 8, followed by caspase 9 and 3
activation. Honokiol prevents interleukin-4-mediated adaptation of CLL cells,
and potentiats the cytotoxicity of chlorambucil, fludarabine, and cladribine.
Honokiol kills myeloma beef from relapsed patients at doses that does not
annihilate PBMCs. Caspase 3, 7, 8, and 9 are induced by honokiol treatment, as
able-bodied as PARP cleavage. Honokiol is begin to abet apoptosis in the colon
blight corpuscle curve RKO. Honokiol potentiates apoptosis, suppresses osteoclastogenesis,
and inhibits aggression through accentuation of nuclear factor-kappaB
activation pathway. Honokiol may act as a almighty anti-inflammatory abettor
with multipotential activities due to an inhibitory aftereffect on the PI3K/Akt
pathway.